HERON THERAPEUTICS, INC. /DE/ (HRTX): Results of Operations and Financial Condition
HERON THERAPEUTICS, INC. /DE/ (HRTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Heron Therapeutics Announces Second Quarter 2026 Financial Results - Q2 2026 net revenue of $37.7 million, up 9% from the first quarter of 2026; ZYNRELEF ® net revenue grew 35% and APONVIE ® net revenue grew 74% year-over-year - Amended credit facility with Hercules
How this was made
The 30-second read
Why it matters
The key tradable change is the withdrawal of full-year 2026 guidance, driven by uncertainty around CINVANTI patent outcomes and potential generic entry timing/terms, plus a pause in sales force expansion and tighter spending. The company also indicates it is considering strategic alternatives.
Market read
Traders should reprice expectations for HRTX’s 2026 revenue and profitability path due to the explicit guidance withdrawal and the court-linked uncertainty around CINVANTI.
What to watch
Investors may be underweighting the magnitude of ZYNRELEF and APONVIE year-over-year growth and the balance-sheet reset via amended Hercules credit covenants, which could stabilize liquidity and execution capacity.
Background
This is an SEC Form 8-K (Item 2.02) with Q2 2026 financial results and updated financing and guidance posture.
Ticker impact
Heron reported Q2 2026 results and withdrew full-year 2026 guidance, citing uncertainty around potential generic entry for CINVANTI after a Delaware court decision.
Near-term downside bias with elevated volatility until investors gain clarity on CINVANTI patent/generic-entry timeline and any strategic-alternatives outcome.
The filing explicitly withdraws full-year guidance and ties the decision to court-driven uncertainty about generic entry for the largest product, which directly affects revenue and EBITDA expectations.
Market effects
Biotech commercial-stage names may see sentiment spillover when patent rulings force guidance withdrawals tied to generic-entry uncertainty.
Primarily impacts US Nasdaq biotech sentiment; limited direct regional spillover beyond healthcare equities.
Low global relevance; mostly company-specific patent and guidance uncertainty.
Counterpoint
The company’s Acute Care franchise growth (ZYNRELEF and APONVIE) and cash balance may reduce downside versus the market’s focus on guidance withdrawal.
Key entities
- issuerHeron Therapeutics, Inc.
Commercial-stage biotech reporting Q2 2026 results, withdrawing full-year 2026 guidance, and discussing balance-sheet reset and strategic alternatives.
- productCINVANTI
Heron’s largest product referenced as having forecast uncertainty for potential generic entry after a Delaware court decision.
- lenderHercules Capital
Counterparty to an amended credit facility with reset covenants through 2027 and potential principal reduction.
